|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,260.50 JPY | -0.77% |
|
-0.53% | +4.05% |
| Capitalization | 1,062B 6.72B 5.79B 5.39B 5.02B 9.35B 610B 10.06B 62.05B 24.47B 291B 25.21B 24.69B | P/E ratio 2026 * |
16x | P/E ratio 2027 * | 14.7x |
|---|---|---|---|---|---|
| Enterprise value | 991B 6.27B 5.4B 5.03B 4.68B 8.72B 569B 9.38B 57.87B 22.82B 271B 23.51B 23.03B | EV / Sales 2026 * |
1.99x | EV / Sales 2027 * | 1.91x |
| Free-Float |
79.73% | Yield 2026 * |
3.45% | Yield 2027 * | 3.46% |
Last Transcript: Ono Pharmaceutical Co., Ltd.
| 1 day | -0.77% | ||
| 1 week | -0.53% | ||
| Current month | +4.05% | ||
| 1 month | +2.80% | ||
| 3 months | +25.51% | ||
| 6 months | +36.17% | ||
| Current year | +4.05% |
| 1 week | 2,214 |  | 2,301.5 |
| 1 month | 2,147.5 | | 2,301.5 |
| Current year | 2,147.5 | | 2,301.5 |
| 1 year | 1,474 | | 2,301.5 |
| 3 years | 1,474 | | 2,966.5 |
| 5 years | 1,474 | | 3,990 |
| 10 years | 1,474 | | 5,880 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gyo Sagara
CEO | Chief Executive Officer | 67 | 31/03/2024 |
Toichi Takino
PSD | President | 57 | 31/03/2024 |
Shinji Takai
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Gyo Sagara
CHM | Chairman | 67 | 31/03/2024 |
Toichi Takino
BRD | Director/Board Member | 57 | 31/05/2020 |
Masao Nomura
BRD | Director/Board Member | 76 | 25/06/2018 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.59% | 3.23% | 27 M€ | |
| -.--% | 0.88% | 0 M€ | |
| -30.99% | 0.67% | 4 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.77% | -0.53% | +40.01% | -21.47% | 6.72B | |
| -1.87% | -3.53% | -5.35% | +61.18% | 44.13B | |
| +1.97% | +2.51% | +51.16% | - | 33.32B | |
| -2.07% | -0.83% | +12.63% | +122.70% | 30.13B | |
| -2.58% | -4.65% | -3.19% | +31.89% | 12.44B | |
| -1.77% | -2.99% | -12.15% | +97.70% | 9.63B | |
| -0.68% | -3.97% | +77.21% | +44.68% | 8.4B | |
| +0.91% | +3.27% | +49.32% | +130.21% | 7.81B | |
| -.--% | +0.14% | - | - | 6.79B | |
| -0.53% | -0.32% | +36.89% | +376.24% | 6.22B | |
| Average | -0.74% | -1.05% | +27.39% | +105.39% | 16.56B | |
| Weighted average by Cap. | -0.82% | -1.16% | +20.30% | +90.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 497B 3.15B 2.71B 2.53B 2.35B 4.38B 285B 4.71B 29.05B 11.45B 136B 11.8B 11.56B | 498B 3.15B 2.72B 2.53B 2.36B 4.38B 286B 4.72B 29.1B 11.47B 136B 11.82B 11.58B |
| Net income | 66.71B 422M 364M 339M 315M 587M 38.3B 632M 3.9B 1.54B 18.27B 1.58B 1.55B | 71.79B 454M 392M 365M 339M 632M 41.22B 680M 4.19B 1.65B 19.66B 1.7B 1.67B |
| Net Debt | -71.53B -453M -390M -363M -338M -630M -41.07B -677M -4.18B -1.65B -19.59B -1.7B -1.66B | -113B -715M -617M -574M -535M -995M -64.91B -1.07B -6.6B -2.6B -30.96B -2.68B -2.63B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 2,260.50 ¥ | -0.77% | 2,116,700 |
| 15/01/26 | 2,278.00 ¥ | -0.28% | 1,909,200 |
| 14/01/26 | 2,284.50 ¥ | +1.02% | 2,363,700 |
| 13/01/26 | 2,261.50 ¥ | -0.48% | 1,874,500 |
| 09/01/26 | 2,272.50 ¥ | +1.00% | 2,201,700 |
Delayed Quote Japan Exchange, January 16, 2026 at 06:30 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4528 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition